Skip Navigation

Neuro-Oncology 2009 11(4):414-422; doi:10.1215/15228517-2008-096
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Jun, P.
Right arrow Articles by Costello, J. F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Jun, P.
Right arrow Articles by Costello, J. F.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright 2009 by the Society for Neuro-Oncology

Epigenetic silencing of the kinase tumor suppressor WNK2 is tumor-type and tumor-grade specific

Peter Jun, Chibo Hong, Anita Lal, Judith M. Wong, Michael W. McDermott, Andrew W. Bollen, Christoph Plass, William A. Held, Dominic J. Smiraglia and Joseph F. Costello

The Brain Tumor Research Center and Department of Neurological Surgery (P.J., C.H., A.L., J.M.W., M.W.M., J.F.C.), and Department of Pathology (A.W.B.), University of California, San Francisco, San Francisco, CA, USA; German Cancer Research Center, Toxicology and Cancer Risk Factors, Heidelberg, Germany (C.P.); Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY, USA (W.A.H., D.J.S.)

Address correspondence to Joseph F. Costello, Department of Neurological Surgery, University of California, San Francisco, Cancer Center, Room N225, 2340 Sutter St., San Francisco, CA 94143, USA (jcostello{at}cc.ucsf.edu).


   Abstract

Both genetic and epigenetic mechanisms contribute to meningioma development by altering gene expression and protein function. To determine the relative contribution of each mechanism to meningioma development, we used an integrative approach measuring copy number and DNA methylation changes genomewide. We found that genetic alterations affected 1.9%, 7.4%, and 13.3% of the 691 loci studied, whereas epigenetic mechanisms affected 5.4%, 9.9%, and 10.3% of these loci in grade I, II, and III meningiomas, respectively. Genetic and epigenetic mechanisms rarely involved the same locus in any given tumor. The predilection for epigenetic rather than genetic silencing was exemplified at the 5' CpG island of WNK2, a serine-threonine kinase gene on chromosome 9q22.31. WNK2 is known to negatively regulate epidermal growth factor receptor signaling via inhibition of MEK1 (mitogen-activated protein kinase kinase 1), and point mutations have been reported in WNK1, WNK2, WNK3, and WNK4. In meningiomas, WNK2 was aberrantly methylated in 83% and 71% of grade II and III meningiomas, respectively, but rarely in a total of 209 tumors from 13 other tumor types. Aberrant methylation of the CpG island was associated with decreased expression in primary tumors. WNK2 could be reactivated with a methylation inhibitor in IOMM-Lee, a meningioma cell line with a densely methylated WNK2 CpG island and lack of WNK2 expression. Expression of exogenous WNK2 inhibited colony formation, implicating it as a potential cell growth suppressor. These findings indicate that epigenetic mechanisms are common across meningiomas of all grades and that for specific genes such as WNK2, epigenetic alteration may be the dominant, grade-specific mechanism of gene inactivation.

Keywords: epigenetic, genetic, meningioma, restriction landmark genome scanning, WNK2

Received July 1, 2008; Accepted October 21, 2008


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.